Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-human Dose Escalation and Optimization Phase I/IIa Study to Investigate Safety, Tolerability, PK, and Efficacy of the NaPi2b ADC TUB-040 in Patients with Platinum-resistant High-grade Ovarian Cancer (PROC) or R/r Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)

Next Previous
Trial Profile

A First-in-human Dose Escalation and Optimization Phase I/IIa Study to Investigate Safety, Tolerability, PK, and Efficacy of the NaPi2b ADC TUB-040 in Patients with Platinum-resistant High-grade Ovarian Cancer (PROC) or R/r Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TUB 040 (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer; Ovarian cancer
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms NAPISTAR1-01
  • Sponsors Tubulis

Most Recent Events

  • 19 Oct 2025 According to a Tubulis media release, the first data from the NSCLC cohort will be presented at a future medical conference. The full abstract will be published in the ESMO Congress 2025 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology.
  • 19 Oct 2025 According to a Tubulis media release, results form this trial were presented at the European Society for Medical Oncology (ESMO) Congress 2025.
  • 19 Oct 2025 Results presented in the Tubulis Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top